Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up
Toxins · 2023
DOI: 10.3390/toxins15090539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Georgia Xiromerisiou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, 41110 Larissa, Greece. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Botulinum Toxins, Type A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We sought to assess the efficacy of combining onabotulinumtoxinA (BoNTA) as add-on therapy to carbamazepine or oxcarbazepine in treatment-refractory patients with trigeminal neuralgia (TGN) who failed to respond (less than 30% response rate) to adequate monotherapy. We conducted a retrospective study on 15 patients with a definite diagnosis of TGN, according to the established criteria, and underwent BoNTA as part of their treatment plan. A single BoNTA session was administered subcutaneously, according to patients’ perceived zone of pain, at different dosages ranging from 30 to 200 units (mean ± standard deviation: 87.3 ± 39.2). All patients (15/15; 100%) reported large reductions in the severity of their TGN-related neuropathic pain. The mean pain score on the VAS scale significantly decreased from 9.3 ± 1.1 to 3.7 ± 1.2 at 2 weeks after injecting BoNTA (p < 0.001) and remained stable at 4 and 24 weeks post-injection. Regarding the impact of BoNTA on patients’ health-related quality of life, there were significant improvements in both the physical and mental health domains (p < 0.05) of SF-36 tool. BoNTA may be a safe and effective treatment option for patients with refractory TGN when added on to carbamazepine or oxcarbazepine. The use of a single BoNTA session for TGN treatment may be an alternative to surgical interventions and as add-on treatment to oral medications, providing patients with a minimally invasive, effective, safe and well-tolerated option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, 41110 Larissa, Greece.
- Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece.
- Euromedica General Clinic, 54645 Thessaloniki, Greece.
- Headache Clinic, Mediterraneo Hospital, 16675 Glyfada, Greece.
- Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, 41110 Larissa, Greece.
- Headache Outpatient Clinic, Department of Neurology, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece.
ORCID-Profile: Georgia Xiromerisiou, Ioannis C Lampropoulos, Emmanouil V Dermitzakis, Michail Vikelis, Chrysoula Marogianni, Dimitrios Mysiris, Andreas A Argyriou
Zitieren
APA
Xiromerisiou, G., Lampropoulos, I. C., Dermitzakis, E. V., Vikelis, M., Marogianni, C., Mysiris, D., & Argyriou, A. A. (2023). Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up. Toxins. https://doi.org/10.3390/toxins15090539
Vancouver
Xiromerisiou G, Lampropoulos IC, Dermitzakis EV, Vikelis M, Marogianni C, Mysiris D, et al. Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up. Toxins. 2023. doi:10.3390/toxins15090539
BibTeX
@article{Xiromerisiou2023,
author = {Xiromerisiou, Georgia and Lampropoulos, Ioannis C and Dermitzakis, Emmanouil V and Vikelis, Michail and Marogianni, Chrysoula and Mysiris, Dimitrios and Argyriou, Andreas A},
title = {Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up},
journal = {Toxins},
year = {2023},
doi = {10.3390/toxins15090539}
}
EUVIMED